Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3‐year retrospective cohort study
Background In the developed world, kidney transplantation (KT) in patients with human immunodeficiency virus (HIV) infection is well established. Developing countries concentrate 90% of the people living with HIV, but their experience is underreported. Regional differences may affect outcomes. Objec...
Saved in:
Published in | Transplant infectious disease Vol. 19; no. 4 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Wiley Subscription Services, Inc
01.08.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 1398-2273 1399-3062 1399-3062 |
DOI | 10.1111/tid.12724 |
Cover
Summary: | Background
In the developed world, kidney transplantation (KT) in patients with human immunodeficiency virus (HIV) infection is well established. Developing countries concentrate 90% of the people living with HIV, but their experience is underreported. Regional differences may affect outcomes.
Objectives
We compared the 3‐year outcomes of patients with HIV infection receiving a KT in two different countries, in terms of incomes and development.
Methods
This was an observational, retrospective, double‐center study, including all HIV‐infected patients >18 years old undergoing KT.
Results
Between 2005 and 2015, 54 KTs were performed (39 in a Brazilian center, and 15 in a Spanish center). Brazilians had less hepatitis C virus co‐infection (5% vs 27%, P=.024). Median cold ischemia time was higher in Brazil (25 vs 18 hours, P=.001). Biopsy‐proven acute rejection (AR) was higher in Brazil (33% vs 13%, P=.187), as were the number of AR episodes (22 vs 4, P=.063). Patient survival at 3 years was 91.3% in Brazil and 100% in Spain; P=.663. All three cases of death in Brazil were a result of bacterial infections within the first year post transplant. At 3 years, survival free from immunosuppressive changes was lower in Brazil (56% vs 90.9%, P=.036). Raltegravir‐based treatment to avoid interaction with calcineurin inhibitor was more prevalent in Spain (80% vs 3%; P<.001). HIV infection remained under control in all patients, with undetectable viral load and no opportunistic infections.
Conclusion
Important regional differences exist in the demographics and management of immunosuppression and antiretroviral therapy. These details may influence AR and infectious complications. Non‐AIDS infections leading to early mortality in Brazil deserve special attention. |
---|---|
Bibliography: | Funding information The study was partially funded by the Spanish Foundation for AIDS Research and Prevention (FIPSE), Madrid (Spain) grant #24‐0858‐09 and by the RETIC, Red de Sida RD12/0017/0001, FEDER, Instituto de Salud Carlos III, Madrid, Spain. J.M.M. received a personal intensification research grant #INT15/00168 during 2016 from the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid (Spain), and a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain during 2017‐19. C.M. received a personal post‐doctoral research grant (Pla Estratègic de Recerca i Innovació en Salut ‐PERIS‐ 2016/2020) from the ‘Departament de Salut de la Generalitat de Catalunya’, Barcelona, Catalonia, Spain during 2017‐2020. 1 See Appendix . ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
ISSN: | 1398-2273 1399-3062 1399-3062 |
DOI: | 10.1111/tid.12724 |